Apixaban Dosing for Stroke Prevention in Nonvalvular Atrial Fibrillation
The standard dose of apixaban is 5 mg orally twice daily for stroke prevention in nonvalvular atrial fibrillation. 1
Standard Dosing Algorithm
Start with 5 mg twice daily unless the patient meets dose reduction criteria. 1
Dose Reduction Criteria
Reduce to 2.5 mg twice daily ONLY if the patient has at least TWO of the following three characteristics: 1
- Age ≥80 years
- Body weight ≤60 kg
- Serum creatinine ≥1.5 mg/dL
This dose reduction strategy was validated in the ARISTOTLE trial, which demonstrated that apixaban 5 mg twice daily (with 2.5 mg twice daily in selected patients meeting these criteria) was superior to warfarin for preventing stroke or systemic embolism (1.27% vs 1.60% per year, HR 0.79), with significantly lower major bleeding rates (2.13% vs 3.09% per year, HR 0.69). 2
Critical Dosing Pitfalls
Do not reduce the dose based on a single criterion alone. A common error in clinical practice is inappropriate dose reduction—studies show that up to 61% of patients receiving reduced-dose apixaban do not meet labeling criteria for dose reduction. 3 Clinicians often inappropriately reduce doses based on age, weight, or renal function individually rather than requiring two of the three criteria. 3
Underdosing may not increase stroke risk disproportionately but paradoxically increases bleeding risk. Real-world data demonstrate that patients receiving inappropriately reduced doses have a 51-66% higher risk of major bleeding compared to those on standard dosing, without clear stroke prevention benefit. 4
Renal Dosing Considerations
The FDA-approved dose reduction criteria already account for renal function through the serum creatinine threshold. No additional dose adjustment is needed for mild-to-moderate renal impairment unless the patient meets the two-of-three criteria above. 1
Apixaban is not recommended in severe renal impairment (CrCl <15 mL/min) or dialysis due to lack of clinical trial evidence. 5
Comparative Efficacy
Apixaban demonstrates superior outcomes compared to alternatives. In the ARISTOTLE trial, apixaban reduced all-cause mortality (HR 0.89) compared to warfarin—a benefit not consistently seen with other DOACs. 6, 7 When compared to aspirin in patients unsuitable for warfarin (AVERROES trial), apixaban reduced stroke/systemic embolism by 55% (HR 0.45) without increasing major bleeding. 2, 8
The number needed to treat with apixaban versus warfarin is 303 to prevent one stroke over one year, with lower intracranial hemorrhage rates (0.2% vs 0.5%). 6